Lilly Just Spent $7 Billion to Skip the Hardest Part of Cancer Treatment

No extraction. No lab manufacturing. No weeks of waiting. No lymphodepleting chemo.

Think of it like updating your phone's software wirelessly instead of mailing it to the manufacturer. The hardware stays where it is; only the instructions travel.

Kelonia's lead program, KLN-1010, targets a protein called BCMA that sits on the surface of multiple myeloma cells. It's currently in a Phase 1 trial (called inMMyCAR) for patients with relapsed or refractory multiple myeloma, meaning their cancer came back or didn't respond to earlier treatments. Early data presented at the 2025 ASH Annual Meeting showed promising tolerability, with no severe cases of cytokine release syndrome (CRS) or neurotoxicity, two of the scariest side effects of traditional CAR-T. The first four patients achieved MRD-negative responses, meaning no detectable cancer remained.

That's early, small-sample data. But for a Phase 1 trial of a completely new treatment approach, it's the kind of signal that gets pharma executives reaching for their checkbooks.

Lilly's In Vivo Shopping Spree

What makes this deal especially interesting is that it's not Lilly's first move in this space. It's not even their second. Just two months earlier, in February 2026, Lilly acquired Orna Therapeutics for up to $2.4 billion, grabbing a different flavor of in vivo CAR-T technology built on circular RNA and lipid nanoparticles rather than viral vectors.

That means Lilly now controls two distinct delivery systems for programming immune cells inside the body: Kelonia's lentiviral approach and Orna's nanoparticle-based platform.

It's a hedge-your-bets strategy, and an expensive one. Between Kelonia and Orna alone, Lilly has committed up to $9.4 billion to in vivo cell engineering. Add in their 2025 acquisition of Verve Therapeutics (up to $1.3 billion, gene editing for cardiovascular disease) and their partnership with Seamless Therapeutics (up to $1.12 billion for gene editing in hearing loss), and the genetic medicine spending spree tops $11 billion.

Where's all this cash coming from? Three letters: GLP-1. Lilly's blockbuster weight-loss and diabetes franchise is generating the kind of revenue that lets you place billion-dollar bets on next-generation platforms without breaking a sweat.

Everyone Wants In on This Race

Lilly isn't the only pharma giant who sees the future in this technology. The competitive landscape looks like a gold rush. Between June and October 2025 alone, big pharma poured $6.6 billion into in vivo CAR-T acquisitions: AbbVie bought Capstan Therapeutics for $2.1 billion, AstraZeneca snagged EsoBiotec for $1 billion, BMS acquired Orbital Therapeutics for $1.5 billion, and Gilead/Kite picked up Interius for $350 million.

The in vivo CAR-T field is rapidly expanding, with numerous disclosed assets globally and multiple programs already in clinical trials. The sheer volume of investment from companies that don't make billion-dollar bets casually tells you something about how seriously the industry is taking this shift.

The Fine Print Nobody Wants to Talk About

For all the excitement, there are real reasons for caution. A diligence brief from Lucid Ventures flagged what it called "unusually early but thin clinical validation" for KLN-1010. Four patients showing clean responses is encouraging; it's not proof that the therapy works long-term.

Durability is the big question mark. Kelonia's lentiviral approach integrates new genetic material permanently into T cells, which theoretically supports lasting responses. But "theoretically" doesn't cut it when you're spending $7 billion. We won't know if these responses hold up for months or years until, well, months and years have passed. Scalability and long-term safety remain unproven, and integrating viral vectors requires 15-year safety monitoring.

There's also the broader challenge facing all in vivo approaches: you can't test the modified cells before they go to work inside the patient. With ex vivo CAR-T, doctors can inspect the product before infusing it. With in vivo, you're pressing "send" and hoping the message lands correctly.

What This Tells Us About Where Pharma Is Headed

Lilly's Kelonia deal isn't just a bet on one drug or one disease. It's a bet on a platform, a new way of delivering genetic medicine that could eventually extend beyond cancer into autoimmune diseases and other conditions.

Kelonia CEO Kevin Friedman called the acquisition a validation of achieving "deep multiple myeloma remissions" with reduced complexity and cost compared to traditional methods. Lilly Oncology president Jacob Van Naarden pointed to KLN-1010's early Phase 1 data as "proof of concept" for overcoming the manufacturing delays, access barriers, and toxicity challenges that have limited current CAR-T therapies.

The real test comes next. Lilly now has to prove that two different in vivo platforms (Kelonia and Orna) can deliver results in larger trials, navigate regulatory pathways, and eventually reach patients at a fraction of what current CAR-T costs. That's a lot of "ifs" stacked on top of each other.

But if even one of these bets pays off, the implications are enormous. Cancer treatment that arrives in an IV bag instead of a manufacturing facility. Genetic medicine as accessible as a flu shot. That's the vision Lilly is writing very large checks to chase.

Flagship Just Invented a New Type of Drug (No, Seriously)

Flagship Pioneering, the firm that built Moderna, just unveiled Serif Biomedicines and a brand-new drug category called Modified DNA. It promises the durability of gene therapy and the flexibility of mRNA, without rewriting your genome. The catch? It still has to prove it works in humans.